Xcout Intel
Immugenia
Immugenia Inc. is a preclinical-stage immuno-oncology company located in Sherbrooke, Quebec, Canada, developing next-generation CAR therapies by engineering hematopoietic stem cells to treat and prevent cancer relapses.
Subscribe to see Immugenia’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Immugenia at a glance
Immugenia is a biotechnology company headquartered in Canada. Its most recent funding round, Pre-Seed, closed in October 2022. Xcout tracks 3 named people at Immugenia, including Stéphane Gagné (Chief Executive Officer).
Immugenia leadership
- Stéphane GagnéChief Executive Officer
- Brigitte LemieuxMarketing Director
- Kathie BélandResearch Director
Immugenia funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Pre-Seed | Undisclosed | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Immugenia competitors
A few of Immugenia's closest competitors — see the full list of competitors and alternatives →
ImmuneBridge Inc. is a biotechnology company headquartered in San Francisco, California, that develops a hematopoietic stem cell (HSC) expansion and differentiation platform.
TATUM Bioscience is a biotechnology research company headquartered in Sherbrooke, Canada, pioneering nanofilament immunotherapy for cancer treatment. Their breakthrough technology is designed to boost tumor visibility and restore anti-tumor immune responses.
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Noile-Immune Biotech Inc. is a biotechnology company incorporated in 2015 and headquartered in Tokyo, Japan. The company specializes in the development of next-generation cancer immunotherapies, including advanced CAR-T cell technologies.
9Bio Therapeutics is a biotechnology company that combines biology, structural engineering, and artificial intelligence to pioneer next-generation biologics for advanced cancers. The company is headquartered in Quebec, Canada.
Cimeio Therapeutics is a privately held, applied gene editing, cellular, and immunotherapy company headquartered in Cambridge, Massachusetts. Founded in 2020, the company is dedicated to transforming hematopoietic stem cell transplantation and cellular therapies.
Get Immugenia's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Immugenia in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access